Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Suppes, T. Search for Related Content PubMed Citation Articles by Suppes, T. Bipolar Disorder Atypical Neuroleptics Anticonvulsants

Maintenance Treatment for Patients With Bipolar I Disorder: Results From a North American Study of Quetiapine in Combination With Lithium or Divalproex (Trial 127)

Trial 127 Investigators

OBJECTIVE: The authors evaluated the efficacy and safety of quetiapine plus lithium or divalproex in the prevention of recurrent mood events in patients with stabilized bipolar I disorder. METHOD: A total of 1,953 patients received open-label quetiapine (400–800 mg/day in flexible, divided doses) with either lithium or divalproex (target serum concentrations 0.5–1.2 meq/liter and 50–125 µg/ml, respectively) for up to 36 weeks. After at least 12 weeks of clinical stability, 628 patients were randomly assigned to double-blind treatment with quetiapine or placebo, in combination with lithium or divalproex, for up to 104 weeks. The primary efficacy measure was time to recurrence of any mood event (mania, depression, or a mixed episode). RESULTS: Fewer patients in the quetiapine group experienced a mood event compared with the placebo group (20.3% versus 52.1%). The hazard ratio for time to recurrence of a mood event was 0.32. Hazard ratios were similar for mania and depression events (0.30 and 0.33, respectively). Sedation, weight increase, and hypothyroidism occurred more frequently in the quetiapine group, as did discontinuations due to adverse events. The incidence and incidence density of a single emergent blood glucose value 126 mg/dl were higher in the quetiapine group (12.6% versus 5.4%; 18.44 versus 9.56 patients per 100 patient-years). Adverse events were generally consistent with the known tolerability profile of quetiapine. CONCLUSIONS: In patients stabilized on quetiapine plus lithium or divalproex, continued treatment was associated with a significant risk reduction in the time to recurrence of any mood event compared with placebo and lithium or divalproex.

This article has been cited by other articles:

				D. BASU and K. CHAKRABORTY Combination Treatment With Quetiapine in Bipolar Disorder Patients Am J Psychiatry, October 1, 2009; 166(10): 1185 - 1185. [Full Text] [PDF]

				B. S. SOMASHEKAR, A. K. JAINER, and W. SHAFI Maintenance Treatment for Patients With Bipolar Disorder Am J Psychiatry, October 1, 2009; 166(10): 1185 - 1185. [Full Text] [PDF]

				A. Rahman, L. M Mican, C. Fischer, and A. H Campbell Evaluating the Incidence of Leukopenia and Neutropenia with Valproate, Quetiapine, or the Combination in Children and Adolescents Ann. Pharmacother., May 1, 2009; 43(5): 822 - 830. [Abstract] [Full Text] [PDF]

				Are Two Medications Better Than One for Initial Treatment of Bipolar Disorder? Journal Watch Psychiatry, April 17, 2009; 2009(417): 1 - 1. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2009 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us